Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNeil proposed aspirin claims "unsupported," Aspirin Foundation of America protests.

This article was originally published in The Tan Sheet

Executive Summary

McNEIL PROPOSED ASPIRIN LABEL WARNINGS "UNSUPPORTED," AFA CLAIMS in June 10 comments to FDA. The Aspirin Foundation of America objects to McNeil's recent proposal to FDA that aspirin labeling advise physician consultation for analgesic or antipyretic use when aspirin is being taken chronically for cardiovascular benefits. "The proposal, like other elements of McNeil's marketing campaign, is wholly unsupported by science and should be categorically dismissed," AFA maintains.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel